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Burkholderia multivorans is a prominent B. cepacia complex (BCC) species causing infection in people with
cystic fibrosis. Despite infection control measures being introduced to reduce the spread of BCC there is a
continued emergence of infections by B. multivorans. Our objective was to analyze a global collection of B.
multivorans isolates, comparing those from environmental and clinical sources with those from reported
outbreaks. Multilocus sequence typing (MLST) was performed on 107 B. multivorans isolates to provide a
detailed analysis of the global population biology of this species. MLST resolved 64 B. multivorans sequence
types. Twelve of these were globally distributed and associated with human infection; two of these (ST-21 and
ST-375) were also composed of environmental isolates. These global lineages included strains previously linked
to large outbreaks (e.g., French epidemic clone ST-16). Though few environmental isolates of B. multivorans
were available for analysis, of six strains identified, three were identical to strains recovered from cystic fibrosis
(CF) infection. Although the ability of B. multivorans to cause CF outbreaks is known, our report here
concerning the existence of globally distributed B. multivorans CF strains is a new observation for this emerging
B. cepacia complex pathogen and suggests that certain strain types may be better adapted to human infection
than others. Common transmission-associated risk factors were not obviously linked to the globally distributed
strains; however, the overlap in strains recovered from water environments, industrial products, and human
infection suggests that environmental sources may be an important reservoir for infection with B. multivorans.
Burkholderia multivorans is one of at least nine closely related
gram-negative species that comprise the B. cepacia complex
(BCC) (35). Originally these species were considered to be onion
pathogens and were subsequently found to possess many benefi-
cial properties for agricultural use (25). However, after more than
two decades they have come to be widely known to cause prob-
lematic pulmonary infections in vulnerable individuals, particu-
larly in people with cystic fibrosis (CF) (9).
B. multivorans and Burkholderia cenocepacia are the two
predominant BCC species causing human infections, though
bacteria from all currently defined BCC species have been
cultured from CF sputum (19, 26, 28). However, most research
has concentrated on B. cenocepacia, which is widely considered
to be the most virulent BCC species, with much less informa-
tion available on B. multivorans. Comparison of recent epide-
miological surveys (4, 12, 28) with older studies (19, 26, 32)
suggests that the proportion of BCC-infected CF patients in-
fected with B. multivorans is rising relative to the proportions
of infection with B. cenocepacia and the remaining BCC spe-
cies, with prevalence in the United States ranging from 38%
(28) to 51% (4) of BCC infections. This proportional rise is
due to a decline in the total incidence of B. cenocepacia while
B. multivorans acquisition has remained steady (D. Henry, D.
Speert, and J. LiPuma, unpublished data). It is unclear why the
incidence of B. cenocepacia has declined and that of B. mul-
tivorans has persisted, but it seems most likely that infection
control measures are effective at limiting the interpatient
spread of “epidemic” B. cenocepacia strains (12, 28). Further-
more, regional differences in B. multivorans recovery rates in
cases of CF result in conflicting reports on the emergence and
epidemiology of B. multivorans in this population (15, 26, 27,
34, 38).
The introduction of stringent infection control measures has
been shown to reduce the incidence of patient-to-patient
spread of B. cenocepacia (5, 26) and presumably has reduced
interpatient spread of other BCC species. However, the con-
tinued emergence of B. multivorans strains (4, 28) suggests
acquisition from other sources, such as the natural environ-
ment. Recent studies have found evidence that supports the
potential for acquisition by humans of BCC, including B. mul-
tivorans, directly from natural environments (1, 14, 18).
The purpose of this study was to characterize the B. mul-
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tivorans population from clinical and environmental sources in
order to evaluate strain distribution and propose mechanisms
explaining its continued emergence in CF infection.
MATERIALS AND METHODS
Strains and culture. The 107 B. multivorans isolates examined in this study
were drawn from the following collections: Cardiff University, Cardiff, Wales,
United Kingdom (1–3, 22); the European B. cepacia Complex Referral Labora-
tory, Gent, Belgium (7, 36); the U.S. B. cepacia Research Laboratory and Re-
pository, Ann Arbor, Michigan (19); and representatives of a published strain
panel (8, 24). These collections contained isolates evaluated in previous molec-
ular epidemiological studies (4, 8, 19, 24). All isolates from clinical sources were
obtained with the consent of patients. Bacteria were cultured and identified using
polyphasic taxonomic approaches as described previously (22). Isolates were all
independently gathered and genetically typed by random amplified polymorphic
DNA analysis (23), recA analysis (22, 36), repetitive extragenic palindromic PCR
using a BOX A1R primer (4), or pulsed field gel electrophoresis (22) prior to
inclusion in the study. All Laboratorium voor Microbiologie, Universiteit Gent
(LMG), strains are available from the Belgium Coordinated Collections of Mi-
croorganisms (http://bccm.belspo.be/).
Multilocus sequence typing. To assess the genetic diversity of this species we
examined isolates evaluated in previous molecular epidemiological studies (4, 8, 19,
24) that were (i) temporally diverse (distributed over a more than 40-year period
from 1966 to 2006), (ii) geographically diverse (isolated in 12 countries on three
continents), and (iii) from samples obtained from a range of natural, industrial, and
clinical (isolates from CF and non-CF patients) environments. We carried out
MLST analysis as previously described for the BCC by use of a single scheme for all
BCC species (2). Each distinct (allele) sequence at each of seven genes was assigned
a unique arbitrary number (allele type). For each allelic profile (considered to be
isogenic when they were indistinguishable at all seven loci) a unique arbitrary se-
quence type (ST) number was assigned. All sequences were deposited in the Burk-
holderia cepacia complex MLST Databases at http://pubmlst.org/bcc/. Novel
sequence information for all seven loci was obtained for 107 B. multivorans isolates.
Analysis of MLST data. To construct gene trees of the concatenated se-
quences (2,773 bp) for the 64 B. multivorans STs, the neighbor-joining Jukes-
Cantor method was used (MEGA v3; http://www.megasoftware.net). The signif-
icance of branching within the trees was evaluated by bootstrap analysis of 1,000
computer-generated trees. The STs within a clonal complex (CC) group were
defined as having at least five MLST loci in common.
RESULTS
Assignment of allele and sequence types. For thorough eval-
uation of the B. multivorans species it was important to use a
collection of strains identified as being diverse on the basis of
analyses of recA sequences, recA-RFLP, repetitive extragenic pal-
indromic-PCR using a BOX A1R primer, random amplified poly-
morphic DNA, and pulsed field gel electrophoresis profiles, pri-
marily to obtain different STs. For each locus all alleles were
found to be of identical lengths (2) for all B. multivorans isolates
examined. Nucleotide sequence diversity was found at all seven
loci as shown in Table 1. The numbers resolved from this BCC
MLST scheme at each locus for B. multivorans ranged from 13
(phaC) to 43 (gyrB) alleles (mean  28.0; Table 1).
Diversity of B. multivorans strains. In order to investigate
the relationships and diversity of the B. multivorans isolates,
two methods were used: concatenation and phylogenetic anal-
ysis of the nucleotide sequences for all seven MLST loci (2).
We analyzed the concatenated sequences (2,773 bp) for the 64
B. multivorans STs alongside the 114 STs of all BCC species
used to validate the BCC MLST scheme (2). B. multivorans
was clearly resolved (100% bootstraps based on 1,000 random-
izations) into a broad cluster distinct from all other BCC spe-
cies (Fig. 1) concurrent with the identification of all isolates as
representing B. multivorans prior to this study. The average
concatenated nucleotide diversity among B. multivorans strains
was 1.0%, with the greatest diversity representing no more
than 2.0% nucleotide divergence. This phylogenetic analysis
identified a separate subgroup within B. multivorans comprised
of STs 188, 194, 308, 320, 390, and 397 (Fig. 1), all of which
demonstrated clear evidence of interspecies recombination
events (see the supplemental material).
Global distribution and regional outbreaks of B. multivorans
infections. In order to determine whether there are globally
distributed B. multivorans strains in cases of CF infection we
examined the prevalence of several isolates previously impli-
cated in cases of patient-to-patient spread among isolates in a
diverse global collection.
A globally distributed strain (ST-16) was found; among the
isolates found in the global distribution was an isolate previ-
ously reported as being an epidemic strain causing patient-
patient spread (31). This isolate, originally reported as part of
another large B. multivorans outbreak in France among 22 CF
patients that was caused by a strain of PCR ribotype X (31),
was identified as ST-16 and was also found to have infected CF
patients in Belgium (strain LMG14273), Australia (BCC0247),
Canada (C6558), and New Zealand (SBL03-088 and SBL04-
172) and a non-CF patient in the United States (CEP0600).
In addition to ST-16, a further 11 STs were identified
among isolates found in more than one country over more
than a decade: ST-17 (New Zealand and the United States),
ST-18 (Canada and the United Kingdom), ST-21 (Canada
and the United States), ST-24 (Canada and Brazil), ST-181
(Czech Republic and New Zealand), ST-190 (Canada and
the United States), ST-195 (Canada and the United King-
dom), ST-198 (Canada and the United States), ST-270
(Canada and Belgium), ST-274 (Australia and New Zeal-
and), and ST-375 (Belgium and Portugal). Note that the
high representation of some countries in this list may be due
largely to ascertainment bias based on disproportionate con-
tribution of isolates to this study. Overall, half of the clonal
complexes identified (CC1, CC4, CC5, and CC6) were
clearly found to be distributed among different countries
(including Canada, the United Kingdom, the United States,
France, Portugal, Belgium, New Zealand, and Australia) on
different continents. A further clonal complex (CC3) was
found in clinical isolations in different countries on the same
continent (Czech Republic and France).
For all cases of implied patient-to-patient spread examined,
unique STs were found in each instance, with no further
matches found within our global collection: ST-27 caused an
outbreak among CF patients in Glasgow (38), ST-25 (previ-
ously named strain OBHM) was shared by U.S. patients (4),
ST-180 caused multiple infections at a single treatment center
TABLE 1. Allelic variation at each locus among 107 B. multivorans
STs examined
MLST locus Allele size (bp) No. of alleles
atpD 443 23
gltB 400 33
gyrB 454 43
recA 393 29
lepA 397 27
phaC 385 13
trpB 301 28
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(Prague, Czech Republic) among CF and non-CF patients,
ST-179 (previously named strain TUL2) was shared by U.S.
patients (4), ST-199 was shared by Canadian siblings with CF
(26), ST-15 caused an outbreak among CF patients in South
Wales (27), and ST-419 was found in an isolate causing an
outbreak among 32 patients in France with PCR ribotype F.
Interestingly, ST-15 (the South Wales outbreak strain) was also
found in a clonal complex (CC1; supplemental material) with
ST-16 (the globally distributed strain also identified as being
part of a French outbreak).
FIG. 1. Phylogenetic tree of concatenated sequence for the MLST alleles for B. multivorans STs in the context of other BCC species by use of
the neighbor-joining Jukes-Cantor method, with STs exhibiting interspecies recombination among the MLST loci indicated.
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Identification of recombination. By comparing the allelic vari-
ations present within clonal complexes, it is possible to suggest
whether the changes are due to point mutation (clonal evolution)
or to recombination events. For example, when six alleles are
identical between two STs in a clonal complex but one allele is
different with respect to numerous nucleotides, this is likely the
result of recombination. However, point mutations usually give
rise to novel alleles, so wherever a change was identified and that
allele was already commonly found in the MLST database, it was
considered to have occurred through recombination (see the sup-
plemental material). Among the eight clonal complexes identi-
fied, the allelic changes mostly appeared to be due to either
intraspecies recombination or interspecies recombination, with
only one change presumably by point mutation (see the supple-
mental material).
As the BCC MLST scheme incorporates at least nine species
in a single approach it facilitates our identification of genetic
exchange between MLST loci of different BCC species. Of the
15 alleles identified as having occurred through recombination
the majority of these (8 alleles; 53%) appear to have arisen
more specifically through interspecies recombination with
other BCC species. In total, among the 64 B. multivorans STs,
12.7% (8 STs) exhibit alleles that are between 3.9% and 7.3%
different from all other B. multivorans alleles and are either the
same as or only one (0.3%) nucleotide divergent from alleles
common to other BCC species (five alleles of B. cenocepacia
[ET-12 lineage], two alleles from B. stabilis, and one allele from
B. cepacia).
DISCUSSION
Typing methods for the unequivocal characterization of iso-
lates are essential for global epidemiological and evolutionary
analysis of bacterial pathogens. However, methodological dif-
ferences in genotyping techniques have thus far limited the
analysis of B. multivorans population genetics. Strain typing
based on the comparison of DNA sequences rather than ge-
nome organizations or restriction fragments is a more reliable
and an unambiguous indicator of strain identification. MLST
has been shown to be an easily transferable, precise, and re-
producible tool for typing BCC species (1, 2, 11, 20, 37). It is a
simple tool that can offer a high level of strain identification
without using polyphasic techniques. The sequence informa-
tion is deposited in an online database resource accessible via
the World Wide Web, which facilitates multicenter collabora-
tive analysis in a way not previously possible. MLST is an
important tool in assessing B. multivorans epidemiology, and it
can be used to clearly identify widely distributed strains and
assist in the global infection control of this pathogens. In the
current study, MLST was for the first time able to demonstrate
the characteristics of globally distributed B. multivorans CF
strains and provide a unique insight into the population biol-
ogy of this pathogen.
The prevalences of each BCC species in CF are not equal,
with B. cenocepacia and B. multivorans being most prominent
(19, 21, 25, 28). Historically, B. cenocepacia strains were re-
sponsible for the largest epidemics among CF communities in
Canada (23, 32) and the United Kingdom (13) during the
1980s and 1990s before strict infection control measures were
introduced (29). In addition, several B. cenocepacia strains
have reached an epidemic status within CF communities and
are extremely virulent. Therefore, the issue of strain transmis-
sibility is of major importance to individuals with CF and the
treatment centers that provide their care. In contrast to B.
cenocepacia, where direct patient-to-patient contact and social-
ization have been reported as the most probable mechanisms
by which infections were spread (13, 26), the mode of trans-
mission for B. multivorans infection has not been determined.
Several reports have identified multiple patients in a specific
area who acquired the same B. multivorans strain at the same
time (4, 26, 27, 31, 38).
MLST concatenated sequence analysis, as predicted from a
previous MLST study, (2), clearly distinguished the 64 B. mul-
tivorans STs from all other BCC species (100% bootstraps).
The diversity seen among the B. multivorans STs corresponds
to that seen in other large studies of the prevalence of B.
multivorans strains in CF patients (26, 34).
Where spread of a B. multivorans strain had been reported,
MLST corresponded in each instance to the original finding
that a single strain type was responsible (see the supplemental
material). No further infections with seven of these outbreak
strains (ST-15, ST-25, ST-27, ST-117, ST-179, ST-199, and
ST-419) have been reported or were found in this study; how-
ever, we were able to identify four independent ST-16 isolates
(see the supplemental material) recovered from clinical infec-
tions outside of France, where the first CF-related outbreak of
this strain was reported (30, 31). B. multivorans ST-16 was
found in six countries on three continents; this represents the
first reported globally distributed B. multivorans strain causing
infections in individuals with and without CF. The global pres-
ence (see the supplemental material) and regional outbreaks
(30, 31) of ST-16 suggest that this B. multivorans strain may
represent a more transmissible CF lineage, such as those of B.
cenocepacia ET-12 (25) and PHDC (6). There was no epide-
miological evidence to link the spread of B. multivorans among
patients of different geographic regions. Although ST-16 was
originally identified as an epidemic strain in France (30, 31)
and has been found to be the most common ST within isolates
examined among different nonsibling patients in the Auckland
area of New Zealand (C. Pope, unpublished data), it does not
appear to have spread within the other four additional loca-
tions in which it has been recovered (see the supplemental
material). This observation may reflect differences in hygiene
policies and host susceptibilities or subtle genomic differences
among isolates of this strain that may have profound effects
upon transmissibility. A finding which adds weight to the no-
tion that ST-16 is perhaps better adapted to human infection
than other B. multivorans strains is that it is just a single-locus
variant (trpB) of ST-15 and hence part of a clonal complex
(CC1; see the supplemental material); thus, two closely related
strain types were each associated with infection in multiple
patients (27, 30, 31).
In total, 18.5% of B. multivorans strains (ST-16, ST-17, ST-
18, ST-21, ST-24, ST-181, ST-190, ST-195, ST-198, ST-270,
ST-274, and ST-375) were found to be dispersed across mul-
tiple countries. The observation that in the same locations,
some genotypes remain unique to individual patients whereas
other genotypes infect several patients is consistent with some
strains having a higher degree of transmissibility, but transmis-
sion may not be via patient contact alone. Acquisition from
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environmental sources should be considered (1), and the prev-
alence of certain strains among clinical isolates may also reflect
the distribution of B. multivorans in contaminated products
and local environments. The recent description of a major
outbreak among CF patients linked to contaminated commer-
cial saline solutions (10) highlights the fact that despite strin-
gent infection control guidelines and the limited individual
contact advocated by the CF community, contamination still
provides a potential source of infection. MLST is highly suited
to identifying such links between source, contamination, and
infection (1, 20).
Though many unique STs were identified in isolates from CF
patients, there was also evidence for B. multivorans strains
having undergone recombination. An ability to exchange ge-
netic material is of growing clinical interest and concern, as
recombination of even a single gene could have profound ef-
fects, including increased resistance to antimicrobials, in-
creased virulence, and potential vaccine immunity in the fu-
ture. Recombination of the MLST loci could be found within
strains from different geographic locations and was not limited
to either just clinical or just environmental isolates. Though we
were able to identify recombination only among the MLST
genes it is unlikely that it is limited to these, and many other
genes not involved in essential processes might recombine at a
higher rate. Certainly systems exist in the BCC to facilitate
recombination, with an extensive presence of insertion se-
quences (16), phages (33), and conjugative transfer genes and
genomic islands (3). We have found evidence that as many as
one in eight B. multivorans strains in this study appear to have
recombined with strains from other species of the BCC.
A large proportion (62.5%) of the interspecies recombina-
tion of MLST loci found for clinical B. multivorans strains was
identified as genetically indistinguishable from that seen with
alleles of B. cenocepacia ET-12 strains. As B. cenocepacia
ET-12 is mainly isolated from clinical settings and not from the
natural environment we assume not only that these species
occupy the same niche but also that genetic exchange is occur-
ring within humans and not in the natural environment. Evi-
dence for this comes from the fact that all the recombination
with the ET-12 lineage was identified within samples isolated
from sputum of CF patients (ST-188, ST-194, ST-308, and
ST-320). In two of these cases (ST-308 and ST-320) an earlier
sputum sample revealed a B. multivorans strain that appeared
to represent the same strain prior to recombination (ST-199
and ST-317). This might imply that recombination has oc-
curred within the CF patient and not simply that acquisition of
a new closely related strain had occurred (37). However, the
patients whose isolates showed the presence of ST-320 and
ST-308 had no exposure to ET-12-infected patients, as it was
absent from the hospital environment; in the case of ST-320,
the hospital has been free of ET-12 for several years. So al-
though it is difficult to identify the specifics of how these re-
combination events occurred, recombination still has an im-
portant, albeit undefined, role in the long-term evolution of
pathogenicity for B. multivorans strains.
As B. multivorans is one of the two most prevalent BCC
species in CF infections (along with B. cenocepacia) it is im-
portant to identify environmental and clinical reservoirs and
the route of acquisition by patients. Though B. multivorans is
infrequently isolated from the natural environment, MLST has
shown that identical STs can be isolated in nature and from
clinical settings (ST-21 and ST-375). As the isolate for ST-375
(R-20526) was from a water source, this may explain the dis-
tribution of B. multivorans strains and their occurrence in geo-
graphically distinct regions (1). Furthermore, ST-373 (R-11581)
was isolated from an industrial product. Our findings are consis-
tent with the view that the use of BCC bacteria by agriculture and
biotechnology industries represents a potential clinical risk to
susceptible members of the community (17). We are currently
seeking to evaluate more thoroughly different ecological niches
such as water sources, industrial processes, and domestic products
in order to identify whether any of them represents a high-risk
source of B. multivorans for CF patients. The ability to carry out
both strain differentiation and species identification in a single
approach and then also to link globally distributed strains repre-
sents a major advance that will greatly enhance the clinical epi-
demiology of B. multivorans infection.
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